UNSPSC 51384632: Phenylbutazone calcium

This classification denotes a nonsteroidal antiinflammatory drug 2C19H19N2O2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RD7H6MM2DL, chemically known as calcium 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione, but more generally known as phenylbutazone calcium, which bears US NIH Compound Identifier 112362. European Medicines Agency schedules Phenylbutazone calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03772MIG.

Most nations, for tariff and trade purposes, schedule phenylbutazone calcium under HS 29331910 and SITC 51571. As of Q4 2014, PHENYLBUTAZONE CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC[C-]1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.CCCC[C-]1C(=O)N(N(C1=O)C2CCCCC2)C3CCCCC3.[CA+2].

UNSPSC 51384632 Phenylbutazone calcium is a Commodity code that nominally designates a specific anti-inflammatory veterinary pharmaceutical; however, recent state and local solicitation activity under this code shows no direct procurement of phenylbutazone calcium itself. Instead, the code has been applied to three separate health-system pharmaceutical and medical-supply initiatives: Seminole County's competitive bidding for naloxone and drug deactivation systems, Texas HHS's exploratory request for information on direct-to-manufacturer prescription programs, and Minnesota's multistate cooperative purchasing alliance solicitation for generic multi-source pharmaceuticals and OTC products. The mismatch between the code's nominal scope and actual procurement activity suggests either miscoding by issuing bodies or administrative use of the code as a catch-all for pharmaceutical and medical-supply acquisitions that do not fit narrower category assignments. State and local issuers under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing consortia administered by state procurement offices (MMCAP through Minnesota Department of Administration).

Recent activity spans Florida, Texas, and Minnesota, with the most concrete solicitation being Seminole County's IFB60459723LAS (due July 26, 2023, posted June 30, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually under a two-year contract with one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building and bidders required to include all shipping and delivery costs. Texas HHS issued RFI HHS0017013 (response deadline April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities for self-insured employer and government health plans. MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) released RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with evaluation weighted 75 percent on price competitiveness and awards effective July 1, 2026. None of these recent opportunities directly align with phenylbutazone calcium procurement, indicating the code shows little relevant recent activity for vendors specializing in that specific pharmaceutical.